CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum

Schnell O, Agarwal A, Azizi M, Ballwieser D, Barnard-Kelly K, Battelino T, Blüher M, Bugianesi E, Cebrian A, Ceriello A, Choudhary P, Danne T, Dayan CM, Del Prato S, Eckel RH, Fioretto P, Garvey T, Green JB, Heerspink HJ, Holman RR, Itzhak B, Jacob S, Jhund PS, Ji L, Judge PK, Khunti K, Korenjak M, Krentz AJ, Lambrinou E, Libby P, Mader JK, Mann JF, Marx N, Mathieu C, McMurray JJ, Müller-Wieland D, Papanas N, Patel DC, Pfeiffer AF, Reger-Tan S, Rodbard HW, Rosano GM, Saboo B, Sato N, Solomon SD, Standl E, Tacke F, Topsever P, Wanner C, Wharton S, Young V (2026)

Publication Type: Journal article, Review article

Publication year: 2026

Journal

Book Volume: 25

Journal Issue: 1

DOI: 10.1186/s12933-026-03140-0

Abstract

The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19-20 November 2026 ( http://www.cvot.org ).

Involved external institutions

Wharton Weight Management Clinic Canada (CA) Sciarc GmbH Germany (DE) Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (HMGU) / Helmholtz Munich Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Acıbadem Üniversitesi Turkey (TR) Universitätsklinikum Würzburg Germany (DE) University of Glasgow United Kingdom (GB) Universitätsklinikum Aachen (UKA) Germany (DE) Democritus University of Thrace (DUTH) / Δημοκρίτειο Πανεπιστήμιο Θράκης Greece (GR) University College London (UCL) United Kingdom (GB) Herz- und Diabeteszentrum Nordrhein-Westfalen Germany (DE) Diacare-Diabetes Care and Hormone Clinic India (IN) Kawaguchi Cardiovascular and Respiratory Hospital / かわぐち心臓呼吸器病院 Japan (JP) Harvard University United States (USA) (US) Peking University People's Hospital (PKUPH) / 北京大学人民医院 China (CN) University of Oxford United Kingdom (GB) University Hospitals of Leicester NHS Trust United Kingdom (GB) King’s College London United Kingdom (GB) Cyprus University of Technology (CUT) / Τεχνολογικό Πανεπιστήμιο Κύπρου Cyprus (CY) Medizinische Universität Graz Austria (AT) KfH-Nierenzentrum / KfH Kidney Centre Germany (DE) Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven Belgium (BE) Clalit Health Services Israel (IL) Université Sorbonne Paris Cité France (FR) Wort & Bild Verlag Konradshöhe GmbH & Co. KG Germany (DE) Hampshire and Isle of Wight Healthcare NHS Foundation Trust United Kingdom (GB) Ljubljana University Medical Centre (Ljubljana UMC) / Univerzitetni klinični center Ljubljana Slovenia (SI) Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung / Helmholtz Institute for Metabolic, Obesity and Vascular Research Germany (DE) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) Health Center Cartagena Old Town / Centro de Salud Cartagena Casco Antiguo Spain (ES) MultiMedica Spa Italy (IT) New University of Lisbon / Universidade Nova de Lisboa Portugal (PT) European Liver Patients' Association (ELPA) Belgium (BE) Cardiff University United Kingdom (GB) Sant'Anna School of Advanced Studies Italy (IT) University of Alberta Canada (CA) University of Colorado Anschutz Medical Campus United States (USA) (US) University of Padua / Universita degli Studi di Padova Italy (IT) University San Raffaele / Università San Raffaele Italy (IT) Cardiology PC United Kingdom (GB) Duke University Health System United States (USA) (US) University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen Netherlands (NL)

How to cite

APA:

Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D., Barnard-Kelly, K., Battelino, T.,... Young, V. (2026). CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum. Cardiovascular Diabetology, 25(1). https://doi.org/10.1186/s12933-026-03140-0

MLA:

Schnell, Oliver, et al. "CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum." Cardiovascular Diabetology 25.1 (2026).

BibTeX: Download